The Safety, Efficacy and Pharmacokinetics of ARQ-151 Cream in Subjects With Chronic Plaque Psoriasis
Status:
Completed
Trial end date:
2019-05-29
Target enrollment:
Participant gender:
Summary
This is a parallel group, double blind, vehicle-controlled study in which ARQ-151 cream 0.3%
or ARQ-151 cream 0.15% or vehicle cream is applied once daily for 84 days to subjects with
chronic plaque psoriasis involving between 2 and 20% body surface area.